Real-world outcomes of two different sensor-augmented insulin pumps with predictive low glucose suspend function in type 1 diabetes patients
| Autor: | P. Olvera, F. Gallego-Gamero, M.T. Herrera, Jesús Moreno-Fernández, José Alberto García-Seco, José Ramón Muñoz-Rodríguez, Pilar Isabel Beato-Víbora |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Adult
Male Insulin pump medicine.medical_specialty Endocrinology Diabetes and Metabolism medicine.medical_treatment Gastroenterology Young Adult Insulin Infusion Systems Endocrinology Internal medicine Diabetes mellitus Internal Medicine medicine Humans Hypoglycemic Agents Insulin Low glucose suspend Glycemic Type 1 diabetes business.industry Real world outcomes General Medicine Middle Aged medicine.disease Hypoglycemia Cross-Sectional Studies Diabetes Mellitus Type 1 Glucose Female business Clinical record |
| Zdroj: | Diabetes Research and Clinical Practice. 181:109093 |
| ISSN: | 0168-8227 |
| DOI: | 10.1016/j.diabres.2021.109093 |
| Popis: | Aim To analyse the real-life outcomes of two sensor-augmented pumps (SAP) with predictive low glucose suspend (PLGS) function, Medtronic Minimed 640G™ with SmartGuard (MM640G) and Tandem T Slim X2™ with Basal-IQ™ (TTSX2), in Type 1 Diabetes Mellitus (T1DM) patients. Methods Observational cross-sectional study using data obtained from computerized clinical records. All T1DM patients on TTSX2 therapy were compared (1:1) with MM640G treated patients selected through stratified sampling. Primary efficacy outcome was to describe time in rage (TIR, 70–180 mg/dL, 3.9–10 mmol/L) interstitial glucose differences according to a non-inferiority hypothesis with TTSX2 compared to MM640G. Results Forty-four patients were analyzed (female 66%). Mean age was 38.9 yrs. (range 23–59 yrs.) and mean diabetes duration was 23.4 ± 9.2 yrs. Patients treated with TTSX2 showed a numerically slightly lower, but non-statistically significantly different, TIR from the MM640G pump group (64.9 ± 16.4% vs. 72.4 ± 17.0%, P = 0.108). Similarly, we did no find differences in HbA1c between T1D patients treated with TTSX2 and MM640G (6.8 ± 1.0% vs. 7.0 ± 0.9%, 51 ± 11 mmol/mol vs. 53 ± 10 mmol/mol, P = 0.312). Moreover, rest of evaluated glycemic outcomes were similar between both treatment groups. Conclusions Patients using two different SAP with PLGS automatic function showed similar glycaemic control in a real-world scenario. NCT04741685. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect